This year, the SITC leadership announced a bold vision for 100 novel IO agents to be approved by 2034. With the announcement of the vision for the next wave of immunotherapy for cancer, SITC published the first manuscript of a five-part series in the Journal for ImmunoTherapy of Cancer (JITC):
“The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)” will serve as the leading resource to chart the path from discovery to oncology patient care.
This JITC Special Series will outline the current state of the field, elevate the most pressing challenges, and propose the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. Read the first manuscript, Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer Strategic Vision, on JITC today.
By the close of 2024, the IO community celebrated six FDA approvals of novel IO agents:
To continue supporting the development of novel IO agents, SITC launched the SITC Biotech Committee this year to lead five strategic pillars to support the entire IO biotech ecosystem as the community navigates the IO drug development pathway.
Led by co-chairs Kristen Hege, MD and Zhen Su, MD, MBA, the Biotech Committee engaged, educated, and created high-yield networking through a diverse set of initiatives.
Kristen Hege, MDBoard Member, Mersana, Adaptimmune, Kelonia and EvolveImmuneBiotech Committee Co-Chair
Zhen Su, MD, MBAMarengo TherapeuticsBiotech Committee Co-Chair